BioVector? Mel202 (M202) Human Uveal Melanoma Cell Line / Mel202 (M202) 人眼葡萄膜黑色素瘤細(xì)胞系

一 產(chǎn)品基本信息與遺傳學(xué)背景

• 細(xì)胞名稱：Mel202（常簡寫為 M202），人眼葡萄膜黑色素瘤細(xì)胞。

• 物種來源：人源（Homo sapiens），雌性（Female）。最初由荷蘭萊頓大學(xué)醫(yī)學(xué)中心（Leiden University Medical Center）Martine Jager 教授團(tuán)隊(duì)從人類原發(fā)性葡萄膜黑色素瘤（Primary Uveal Melanoma, UM）組織中分離并成功建立株系。該細(xì)胞作為歐洲委員會(huì)第五框架基礎(chǔ)設(shè)施項(xiàng)目“ESTDAB”（歐洲可檢索腫瘤細(xì)胞系數(shù)據(jù)庫）的一部分（編號(hào)：ESTDAB-128），獲得了極清晰的免疫學(xué)與遺傳學(xué)背景表征。

• 遺傳學(xué)與突變特征（關(guān)鍵背景）：

  • GNAQ 突變（經(jīng)典特征）：Mel202 細(xì)胞攜帶 GNAQ 基因經(jīng)典熱點(diǎn)激活突變（p.Gln209Leu / c.626A>T）。超過 80% 的原發(fā)性葡萄膜黑色素瘤具備 GNAQ 或 GNA11 突變，這導(dǎo)致其下游的 MAPK 信號(hào)通路（RAS-RAF-MEK-ERK）及 YAP/TAZ 通路發(fā)生結(jié)構(gòu)性持續(xù)激活。

  • SF3B1 突變：同時(shí)攜帶剪切因子基因 SF3B1 突變（p.Arg625Gly），該突變通常與葡萄膜黑色素瘤晚期發(fā)生轉(zhuǎn)移的風(fēng)險(xiǎn)密切相關(guān)。

  • CDKN2A 突變：存在 CDKN2A 基因失活突變（p.Leu65Argfs*52），導(dǎo)致細(xì)胞周期檢查點(diǎn)調(diào)控機(jī)制缺陷。

  • BAP1 狀態(tài)：保留了 BAP1 的表達(dá)（BAP1-wildtype / BAP1-positive），這符合其源自非高度惡性早期/或特定轉(zhuǎn)移表型原發(fā)灶的生物學(xué)特征。

• 免疫學(xué)標(biāo)志物：HLA 分型明確（如 HLA-A*02:01 陽性）。表達(dá)黑色素瘤相關(guān)抗原 MART-1（Melan-A）。這使其成為黑色素瘤免疫治療研究中少數(shù)兼具特定 HLA 限制性與特異性抗原表達(dá)的細(xì)胞模型。

• 生長特性：貼壁生長（Adherent），主要呈現(xiàn)上皮細(xì)胞樣（Epithelial-like）、梭形或多角形交織生長形態(tài)，細(xì)胞形態(tài)較為緊湊。

• 生物安全級(jí)別：1-2 級(jí)（BSL-1/2）。雖然源自人類原發(fā)腫瘤，但在常規(guī)操作中仍需作為潛在的人源傳染源，在二級(jí)生物安全柜內(nèi)執(zhí)行規(guī)范的標(biāo)準(zhǔn)細(xì)胞房操作。

二 核心科研價(jià)值與轉(zhuǎn)化醫(yī)學(xué)應(yīng)用

Mel202 細(xì)胞在眼部腫瘤學(xué)以及靶向治療耐藥機(jī)制研究中具有不可替代的作用：

1. 葡萄膜黑色素瘤靶向藥物篩選與耐藥機(jī)制（Targeted Therapy & MAPK Inhibition）：

   由于皮膚黑色素瘤通常由 BRAF 突變（如 $BRAF^{V600E}$）驅(qū)動(dòng)，而眼部葡萄膜黑色素瘤（UM）主要由 GNAQ/GNA11 驅(qū)動(dòng)，因此對(duì)常規(guī)的 BRAF 抑制劑天然耐藥。Mel202 作為典型的 GNAQ 突變細(xì)胞模型，被廣泛用于開發(fā)和評(píng)價(jià)新型 MEK 抑制劑（如 Trametinib, Selumetinib, TAK733）、PKC 抑制劑以及 ARF6 抑制劑的單藥或聯(lián)合用藥毒殺動(dòng)力學(xué)。

2. 過繼性免疫治療與 T 細(xì)胞毒性評(píng)估（Immunotherapy & CTL Assay）：

   由于 Mel202 穩(wěn)定表達(dá) MART-1 抗原且 HLA-A*02:01 呈陽性，它是評(píng)價(jià) MART-1 特異性細(xì)胞毒性 T 淋巴細(xì)胞（CTL）或 TCR-T 細(xì)胞體外靶向殺傷效能、細(xì)胞因子（如 IFN-$\gamma$、TNF-$\alpha$）釋放反應(yīng)的國際標(biāo)準(zhǔn)靶細(xì)胞模型，常用于研究放化療敏化劑（如順鉑 CDDP）如何通過上調(diào) FasR 增強(qiáng) CTL 對(duì)其的非特異性清除。

3. 眼部腫瘤體內(nèi)移植瘤模型構(gòu)建（Xenograft Modeling）：

   可在免疫缺陷型小鼠（如 BALB/c Nude、NOD-SCID）皮下、或原位眼壓前房/脈絡(luò)膜接種構(gòu)建眼部黑色素瘤移植瘤模型，用于觀察腫瘤在眼部微環(huán)境中的原位浸潤、以及研究其自發(fā)向肝臟等遠(yuǎn)端器官轉(zhuǎn)移的靶向偏好性。

三 實(shí)驗(yàn)室細(xì)胞復(fù)蘇、擴(kuò)增傳代與冷凍保存標(biāo)準(zhǔn)步驟

1. 完全培養(yǎng)基配置

Mel202 細(xì)胞在常規(guī)含營養(yǎng)素的基質(zhì)中生長良好，但需要充足的谷氨酰胺支持：

• 基礎(chǔ)培養(yǎng)基：RPMI 1640 培養(yǎng)基（推薦）（含 2.0 mM L-Glutamine 谷氨酰胺）。

• 完全添加劑成分：

  • 10% 優(yōu)質(zhì)滅活胎牛血清（FBS）。

  • 1% 滅菌雙抗（Penicillin-Streptomycin, 100 U/mL）。

• 培養(yǎng)條件：37 攝氏度、5% $CO_2$、恒濕環(huán)境培養(yǎng)箱。

2. 細(xì)胞復(fù)蘇步驟

1. 將配置好的完全培養(yǎng)基在 37 攝氏度水浴中提前預(yù)熱。

2. 從液氮罐中迅速取出 Mel202 的凍存管，立刻整管投入 37 攝氏度恒溫水浴箱中，輕微規(guī)律晃動(dòng)。

3. 在 1 分鐘之內(nèi)令管內(nèi)細(xì)胞急速融化（當(dāng)內(nèi)部僅剩最后一粒微小冰芯時(shí)撈出）。迅速用 75% 酒精擦拭凍存管外部消毒。

4. 在無菌生物安全柜內(nèi)，用移液槍吸出細(xì)胞懸液，置于含有 5 mL 預(yù)熱完全培養(yǎng)基的 15 mL 離心管中，輕柔緩慢地顛倒混勻以平衡滲透壓。

5. 以 200 - 300 x g（約 1000 rpm）離心 3 - 4 分鐘，小心吸除含有 DMSO 保護(hù)劑的上清液。

6. 加入 5 mL 新鮮完全培養(yǎng)基，用移液槍極其輕柔地吹打重懸細(xì)胞沉淀。

7. 接種于 T25 培養(yǎng)瓶中，置于 37 攝氏度、5% $CO_2$ 孵箱中培養(yǎng)。次日通過倒置顯微鏡觀察細(xì)胞的貼壁展平形態(tài)及存活率。

3. 細(xì)胞傳代與消化方法

• 傳代時(shí)機(jī)：當(dāng)細(xì)胞表面融合度達(dá)到 70% - 80% 時(shí)，必須及時(shí)傳代。盡量避免細(xì)胞 100% 長滿，否則緊密接觸抑制會(huì)導(dǎo)致細(xì)胞老化或形態(tài)向不規(guī)則巨型多核轉(zhuǎn)化。

• 傳代比例：新接種密度建議控制在 $1 \times 10^4$ 至 $4 \times 10^4\text{ cells/cm}^2$，通常按照 1:3 至 1:4 的比例進(jìn)行分瓶傳代，每 3 - 4 天傳代一次。

• 操作步驟：

  1. 吸除吸干舊的培養(yǎng)基。用無菌的無鈣鎂離子 PBS 輕輕洗滌細(xì)胞表面 1 - 2 次，清除殘留血清。

  2. 加入適量的 0.25% Trypsin-EDTA 消化液（T25 瓶常規(guī)加入 1 mL），使其均勻覆蓋整個(gè)貼壁細(xì)胞層。

  3. 放入 37 攝氏度孵箱中消化 2 至 4 分鐘。在倒置顯微鏡下連續(xù)觀察，當(dāng)大部分上皮樣細(xì)胞收縮變圓、細(xì)胞間隙明顯增大、且輕擊瓶壁細(xì)胞開始大面積成片滑落時(shí)，立即加入 2 倍體積的含血清完全培養(yǎng)基終止消化。

  4. 用移液槍平穩(wěn)吹打瓶壁，使貼壁細(xì)胞完全解離分散為單細(xì)胞懸液。收集至離心管中，300 x g 離心 3 分鐘，棄上清。

  5. 加入適量新鮮完全培養(yǎng)基，吹勻后按比例接種到新的培養(yǎng)瓶/孔板中。

4. 細(xì)胞冷凍保存

• 凍存液配方：90% 完全培養(yǎng)基（或純 FBS） + 10% 優(yōu)質(zhì)細(xì)胞級(jí) DMSO。

• 凍存操作：冷凍前確保細(xì)胞處于對(duì)數(shù)生長活躍期，且活力達(dá) 90% 以上。離心收集細(xì)胞沉淀，調(diào)整最終細(xì)胞密度至 $1.5 \times 10^6$ 至 $3 \times 10^6\text{ cells/vial}$。加入凍存液重懸分裝至凍存管中，立即投入標(biāo)準(zhǔn)程序降溫盒內(nèi)（如 Mr. Frosty 梯度降溫盒，維持 -1 攝氏度/分鐘的降溫速度），置于 -80 攝氏度冰箱過夜，次日必須迅速轉(zhuǎn)移至 -196 攝氏度液氮罐中長期冷凍保存。

Part 2 English Section

I General Information and Genetic Architecture

• Cell Line Designation: Mel202 (commonly abbreviated as M202), Human Uveal Melanoma Cell Line.

• Species Origin: Homo sapiens (Human), Female.Originally isolated and characterized by Professor Martine Jager and colleagues at the Department of Ophthalmology, Leiden University Medical Center, Netherlands. It was recovered from a patient's primary uveal melanoma (UM) in situ tissue. As a foundational matrix of the European Commission's fifth framework infrastructure program "ESTDAB" (Database registration code: ESTDAB-128), its immunogenetic, mutation, and HLA parameters are fully mapped.

• Genomic and Mutational Profiles (Critical Background):

  • GNAQ Hyper-activation (Canonical Driver): Mel202 harbors the classical, hotspot oncogenic activation mutation in GNAQ (p.Gln209Leu / c.626A>T). This driver configuration is found in over 80% of primary ocular melanomas, causing structural hyper-activation of downstream MAPK cascades (RAS-RAF-MEK-ERK pathway) and YAP/TAZ signaling circuits.

  • SF3B1 Comutations: Possesses the splicing factor SF3B1 variant (p.Arg625Gly), a genetic hallmark tightly correlated with intermediate-to-high clinical metastatic dissemination profiles in uveal melanoma.

  • CDKN2A Loss: Features a frameshift regulatory knockout mutation in CDKN2A (p.Leu65Argfs*52), resulting in compromised cell cycle G1/S checkpoint governance.

  • BAP1 Phenotype: Retains normal, wildtype BAP1 protein output (BAP1-wildtype/positive), aligning with its origin from a primary tumor niche prior to entering extreme high-grade malignant clonal evolution.

• Immunological Baseline: Characterized by distinct human leukocyte antigen (HLA) restrictions, presenting as HLA-A*02:01 positive. It maintains stable structural expression of the melanoma-associated lineage antigen MART-1 (Melan-A), making it a rare, essential ocular model serving restricted immunotherapeutic engineering.

• Growth Topology & Morphology: Adherent matrix. Manifests predominantly as differentiated epithelial-like, polygonal, or interlaced spindle morphologies forming cohesive, dense single-layer clusters.

• Biosafety Matrix: Classified under Biosafety Level 1 or 2 (BSL-1/2). As a human-derived primary carcinoma lineage, all operational maintenance must proceed inside verified Class II Biosafety Cabinets under standardized sterile clinical lab routines.

II Strategic Research Value and Translational Fields

The Mel202 line serves as an indispensable in vitro platform to navigate ocular oncogenesis, signal transduction network mapping, and multi-drug targeted resistance:

1. Targeted Small-Molecule Screenings & MAPK Re-routing Cascades:

   Unlike cutaneous melanomas frequently driven by BRAF alterations (e.g., $BRAF^{V600E}$), uveal melanoma (UM) utilizes autonomous GNAQ/GNA11 upstream links, displaying universal intrinsic resistance against clinical BRAF inhibitors. Mel202 functions as the benchmark GNAQ-mutant preclinical target to discover, screen, and optimize novel MEK inhibitors (e.g., Trametinib, Selumetinib, TAK733), PKC inhibitors, or ARF6-directed blocking strategies, mapping single or combination synergistic lethality.

2. Adoptive Immunotherapy Competence & T-Cell Cytotoxicity Assays:

   Because Mel202 expresses intact MART-1 targets in tandem with the HLA-A*02:01 restriction axis, it is utilized worldwide as a validation platform to capture the lytic potency of MART-1-primed Cytotoxic T Lymphocytes (CTLs) or engineered TCR-T constructs. It assists in tracking effector cytokine discharge kinetics (IFN-$\gamma$, TNF-$\alpha$) and studying how chemotherapeutic regimens (e.g., Cisplatin / CDDP) sensitize immune non-responsive targets by up-regulating death-receptor FasR.

3. In Vivo Ocular Model Assemblies (Orthotopic Ocular Xenografts):

   Aids in the generation of standard subcutaneous tumor models or advanced orthotopic intraocular (anterior chamber or suprachoroidal space) xenografts within immunodeficient mice (e.g., BALB/c Nude, NOD-SCID). This models how ocular malignancies behave under the unique structural microenvironment of the eye and tracks mechanisms driving its dedicated organotrophic metastasis toward hepatic tissues.

III Thawing, Proliferation, Passaging, and Cryopreservation Routines

1. Formulating the Complete Growth Medium

Mel202 demands standard metabolic substrates but requires rigorous replenishment of L-glutamine reserves:

• Basal Medium: RPMI 1640 Growth Medium (Highly Recommended) (pre-fortified with 2.0 mM L-Glutamine).

• Complete Supplements:

  • 10% Premium Heat-Inactivated Fetal Bovine Serum (FBS).

  • 1% Sterilized Penicillin-Streptomycin cocktail (100 U/mL final working threshold).

• Environment: 37°C under a humidified atmosphere containing 5% $CO_2$.

2. Cryovial Thawing Routine

1. Pre-warm the formulated complete growth medium inside a 37°C water bath.

2. Extract the Mel202 cryovial from liquid nitrogen storage and instantly submerge it into the 37°C water bath with gentle, continuous horizontal agitation.

3. Achieve complete liquefaction rapidly within 1 minute (remove when a minimal frozen core remains). Swab the exterior thoroughly with 75% ethanol.

4. In a sterile biosafety hood, transfer the cell suspension into a 15 mL tube containing 5 mL of pre-warmed complete growth medium. Mix by smooth inversion to mitigate sudden osmotic shock.

5. Centrifuge at 200–300 × g (~1000 rpm) for 3–4 minutes, then cleanly aspirate the DMSO-laden supernatant.

6. Replenish with 5 mL of fresh complete medium, and smoothly resuspend the pellet via gentle pipetting.

7. Transfer the suspension into a T25 culture flask, and incubate at 37°C with 5% $CO_2$. Assess cell attachment profiles, alignment, and post-thaw viability under an inverted microscope the following day.

3. Subculturing and Cell Passaging Guide

• Confluency Cutoff: Subculturing must occur precisely when the monolayer hits 70%–80% confluency. Do not permit the sheet to hit absolute 100% saturation, as prolonged contact inhibition forces irreversible senescence or shifts cells toward giant multinucleated aberrant structures.

• Split Ratios & Seeding Density: Calibrate seeding densities to a baseline of $1 \times 10^4$ to $4 \times 10^4\text{ cells/cm}^2$. Split the flasks utilizing standard ratios ranging from 1:3 to 1:4 every 3 to 4 days.

• Step-by-Step Harvesting Routine:

  1. Aspirate spent medium and rinse the cell sheet 1–2 times with sterile, calcium/magnesium-free PBS to remove residual serum proteins that neutralize trypsin.

  2. Add an appropriate volume of 0.25% Trypsin-EDTA Solution (approx. 1 mL for standard T25 flasks) to completely submerge the layer.

  3. Incubate at 37°C for 2 to 4 minutes. Monitor continuously under an inverted microscope; as soon as the epithelial-like boundaries round up, contract, and begin detaching upon gentle mechanical tapping against the side of the flask, instantly add a double volume of serum-containing complete growth medium to quench enzymatic degradation.

  4. Gently pipette the vessel surfaces to yield a homogeneous single-cell suspension. Centrifuge at 300 × g for 3 minutes, then discard the supernatant fluid.

  5. Disperse the pellet into fresh complete medium, split according to target ratios, and allocate into new culture vessels.

4. Cryopreservation Protocol

• Freezing Medium Matrix: 90% Complete Growth Medium (or pure premium FBS) supplemented with 10% analytical-grade cell-culture DMSO.

• Freezing Routine: Harvest active, log-phase cells showing >90% cell viability metrics. Centrifuge and resuspend the cell mass to hit a final concentration baseline of $1.5 \times 10^6$ to $3 \times 10^6\text{ cells/vial}$. Aliquot into sterile cryovials and transfer immediately into a standardized controlled-rate freezing box (e.g., Mr. Frosty container, ensuring a constant thermal drop profile of -1°C/minute). House at -80°C overnight, and shift the vials into the liquid nitrogen vapor phase (-196°C) the following day for long-term preservation.

BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號(hào):1843439339

網(wǎng)址http://www.nedfriskphoto.com